Experienced in Upper Tract Urothelial Carcinoma (UTUC)

Dr. Daniel J. George

Urology | Hematology | Oncology
Duke Health Integrated Practice Inc
2351 Erwin Rd, 
Durham, NC 
Accepting New Patients
Offers Telehealth
Experienced in Upper Tract Urothelial Carcinoma (UTUC)
Duke Health Integrated Practice Inc
2351 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel George is a Urologist and a Hematologist in Durham, North Carolina. Dr. George is rated as an Experienced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy. Dr. George is currently accepting new patients.

His clinical research consists of co-authoring 324 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Hematology
Oncology
Licenses
Urology in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
6301 Herndon Rd, Durham, NC 27713
DUKE HEALTH INTEGRATED PRACTICE INC
1234 Huffman Mill Rd, Burlington, NC 27215
DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710
DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race
Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: ARN-509, Abiraterone Acetate, Prednisone
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Enrollment Status: Terminated
Publish Date: April 30, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

323 Total Publications

What we can learn from a national tumor pathology registry.
What we can learn from a national tumor pathology registry.
Journal: Cancer
Published: December 15, 2025
Similar Doctors
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Brant A. Inman
Urology
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Brant A. Inman
Urology
1000 Trent Dr, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brant Inman is a Urologist in Durham, North Carolina. Dr. Inman is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Inman is currently accepting new patients.

Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Michael R. Harrison
Oncology | Hematology
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Michael R. Harrison
Oncology | Hematology

Duke Health Integrated Practice Inc

2301 Erwin Rd, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Harrison is an Oncologist and a Hematologist in Durham, North Carolina. Dr. Harrison is rated as a Distinguished provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Prostatectomy. Dr. Harrison is currently accepting new patients.

Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Sundhar Ramalingam
Oncology
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Sundhar Ramalingam
Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.3 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sundhar Ramalingam is an Oncologist in Durham, North Carolina. Dr. Ramalingam is rated as a Distinguished provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), and Clear Cell Sarcoma. Dr. Ramalingam is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. George's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile